SK2442004A3 - Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure - Google Patents

Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure Download PDF

Info

Publication number
SK2442004A3
SK2442004A3 SK244-2004A SK2442004A SK2442004A3 SK 2442004 A3 SK2442004 A3 SK 2442004A3 SK 2442004 A SK2442004 A SK 2442004A SK 2442004 A3 SK2442004 A3 SK 2442004A3
Authority
SK
Slovakia
Prior art keywords
present
treatment
atomoxetine
dementia
schizophrenia
Prior art date
Application number
SK244-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Franklin Porter Bymaster
Donald Richard Gehlert
David Lee Mckinzie
Charles Renkin Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SK2442004A3 publication Critical patent/SK2442004A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SK244-2004A 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure SK2442004A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (1)

Publication Number Publication Date
SK2442004A3 true SK2442004A3 (en) 2004-12-01

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
SK244-2004A SK2442004A3 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Country Status (26)

Country Link
US (1) US20050009925A1 (cs)
EP (1) EP1458368B1 (cs)
JP (1) JP2005517647A (cs)
KR (1) KR20040066895A (cs)
CN (1) CN1713900A (cs)
AU (1) AU2002352625A1 (cs)
BR (1) BR0213581A (cs)
CA (1) CA2467802A1 (cs)
CO (1) CO5590907A2 (cs)
CZ (1) CZ2004709A3 (cs)
DE (1) DE60223718T2 (cs)
EA (1) EA200400793A1 (cs)
EC (1) ECSP045145A (cs)
ES (1) ES2295435T3 (cs)
HR (1) HRPK20040528B3 (cs)
HU (1) HUP0402619A3 (cs)
IL (1) IL161989A0 (cs)
MX (1) MXPA04005716A (cs)
MY (1) MY136367A (cs)
NO (1) NO20042904L (cs)
NZ (1) NZ532065A (cs)
PL (1) PL369311A1 (cs)
SK (1) SK2442004A3 (cs)
TW (1) TW200300672A (cs)
WO (1) WO2003049724A1 (cs)
ZA (1) ZA200404274B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0313411A (pt) * 2002-08-14 2005-06-28 Pharmacia & Upjohn Co Llc Uso de reboxetina para o tratamento de ondas de calor
EP1708717B1 (en) * 2003-07-28 2011-10-05 Leslie Joe Dunaway Atomoxetine for treatment of allergic rhinitis and asthma
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
DE602004014823D1 (de) * 2003-12-12 2008-08-14 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
US20110028453A1 (en) * 2009-07-31 2011-02-03 Wen-Mei Fu Treating Negative Symptoms of Schizophrenia Associated with Defective Neuregulin 1
US20140249180A1 (en) * 2011-10-03 2014-09-04 National Center For Geriatrics And Gerontology Tau aggregation inhibitor
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6313750B2 (ja) 2013-04-02 2018-04-18 学校法人同志社 タウ凝集阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
ATE319453T1 (de) * 1999-07-01 2006-03-15 Pharmacia & Upjohn Co Llc Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
NZ517696A (en) * 1999-10-13 2004-12-24 Pfizer Prod Inc Biaryl ether derivatives useful as monoamine reuptake inhibitors
WO2002053140A2 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory

Also Published As

Publication number Publication date
EA200400793A1 (ru) 2004-10-28
NO20042904L (no) 2004-09-07
PL369311A1 (en) 2005-04-18
HRP20040528A2 (en) 2004-10-31
DE60223718T2 (de) 2008-10-30
EP1458368B1 (en) 2007-11-21
ZA200404274B (en) 2005-09-13
CO5590907A2 (es) 2005-12-30
JP2005517647A (ja) 2005-06-16
WO2003049724A1 (en) 2003-06-19
ECSP045145A (es) 2004-07-23
KR20040066895A (ko) 2004-07-27
EP1458368A1 (en) 2004-09-22
CA2467802A1 (en) 2003-06-19
US20050009925A1 (en) 2005-01-13
IL161989A0 (en) 2005-11-20
HRPK20040528B3 (en) 2006-03-31
NZ532065A (en) 2007-03-30
DE60223718D1 (de) 2008-01-03
CZ2004709A3 (cs) 2004-10-13
CN1713900A (zh) 2005-12-28
HUP0402619A3 (en) 2008-04-28
MXPA04005716A (es) 2004-12-06
HUP0402619A2 (hu) 2005-03-29
AU2002352625A1 (en) 2003-06-23
ES2295435T3 (es) 2008-04-16
TW200300672A (en) 2003-06-16
MY136367A (en) 2008-09-30
BR0213581A (pt) 2004-08-24

Similar Documents

Publication Publication Date Title
US9808455B2 (en) Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
JP2006515628A (ja) ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
EP1238676B1 (en) Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis
US20050004106A1 (en) Combinations of GABA modulators and anticonvulsants, and atypical antipsychotics
CA2332814C (en) Combination therapy for treatment of refractory depression
SK2442004A3 (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
CZ2001677A3 (cs) Farmaceutický prostředek
AU4008899A (en) Combination therapy for treatment of bipolar disorders
MX2007011436A (es) Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas.
MXPA05013877A (es) Asociacion de antagonista o agonista inverso del receptor h3 de histamina con anti-psicotico o antidepresivo y su utilizacion para preparar medicamento que prevenie los efectos indeseables de medicamentos psicotropicos.
KR20080107429A (ko) 정신병적 장애의 치료 또는 예방용의 신규한 치료학적 배합물
US20050119253A1 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN115515590A (zh) 马赛替尼用于治疗多发性硬化患者亚群
KR20060032633A (ko) 벤조디아제핀 수용체의 알파 3 서브유닛에 대한 선택성을갖는 화합물을 사용한 중추신경계 장애의 치료 또는 예방방법
SK14502000A3 (sk) Kombinácie liekov n. a. r. i. (inhibítorov reaktivácie noradrenalínu), výhodne reboxetínu, a pindololu
RU2508106C2 (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
RU2238084C2 (ru) Композиции, содержащие ингибиторы обратного захвата допамина, и способы их применения
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
Doran The Dopamine Hypothesis Revisited
MXPA00011353A (es) Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria
CA2617420A1 (en) Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines

Legal Events

Date Code Title Description
FC9A Refused patent application